Type 2 diabetes
Conditions
Interventions
Imeglimin 2000mg/day for 16 weeks
Sponsors
Toho university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients with type 2 diabetes (2)Patients with an eGFR of 45mL/min/1.73m2 or more (3)Patients aged 20 to 80 (4)Patients who have the avility to consent to participation in this study and who can understand the consent form and other explanatory documents (5) Patients who have been treated with monotherapy of DPP-4 inhibitors in the past 3months
Exclusion criteria
Exclusion criteria: (1)Type 1 diabetes mellitus patients (2)Patients with severe liver disease or AST (GOT) or ALT (GPT) >100 IU/L (3)Patients with serious renal disease and patients with a serum creatinine level of 2.0 mg/dL or higher before the start of the study (4)Patients with overt heart failure and those who had myocardial infarction within 3 months before the start of the study (5)Patients with severe pancreatic disease (6)Patients with acute stage/serious condition that may cause change in condition due to blood sugar fluctuation or addition of drugs (7)Patients with serious infections or serious trauma. Patients before and after surgery (8)Patients with severe chronic bowel disease accompanied by inflammatory bowel disease, colonic ulcer, focal bowel obstruction, bowel obstruction predisposition, or digestive/absorptive disorders (9) Excessive habitual drinkers (10) Pregnant women, women who may be pregnant, women who wish to become pregnant, and women who are breastfeeding (11) Patients who are judged to be inappropriate by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of the AUC insulin/AUC glucose between pre and post intervention | — |
Countries
Japan
Contacts
Public ContactAtsushi Itsukaichi
Toho University School of Medicine Divsion of diabetes, metabolism and endocrinology
Outcome results
None listed